JP2024503425A - 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 - Google Patents

黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 Download PDF

Info

Publication number
JP2024503425A
JP2024503425A JP2023542502A JP2023542502A JP2024503425A JP 2024503425 A JP2024503425 A JP 2024503425A JP 2023542502 A JP2023542502 A JP 2023542502A JP 2023542502 A JP2023542502 A JP 2023542502A JP 2024503425 A JP2024503425 A JP 2024503425A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503425A5 (https=
Inventor
毛 毛 安
熙 然 邱
思 敏 陳
詩 雨 郭
博 華 李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Starmab Biologics Shanghai Co Ltd
Starmab Biologics Suzhou Co Ltd
Original Assignee
Starmab Biologics Shanghai Co Ltd
Starmab Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Starmab Biologics Shanghai Co Ltd, Starmab Biologics Suzhou Co Ltd filed Critical Starmab Biologics Shanghai Co Ltd
Publication of JP2024503425A publication Critical patent/JP2024503425A/ja
Publication of JP2024503425A5 publication Critical patent/JP2024503425A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2023542502A 2021-01-11 2022-01-11 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用 Pending JP2024503425A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110033695 2021-01-11
CN202110033695.3 2021-01-11
PCT/CN2022/071382 WO2022148480A1 (zh) 2021-01-11 2022-01-11 靶向金黄色葡萄球菌α-毒素的抗原结合蛋白及其应用

Publications (2)

Publication Number Publication Date
JP2024503425A true JP2024503425A (ja) 2024-01-25
JP2024503425A5 JP2024503425A5 (https=) 2025-01-29

Family

ID=82357142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542502A Pending JP2024503425A (ja) 2021-01-11 2022-01-11 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用

Country Status (7)

Country Link
US (1) US20240059764A1 (https=)
EP (1) EP4286409A4 (https=)
JP (1) JP2024503425A (https=)
KR (1) KR20230147616A (https=)
CN (1) CN117062908A (https=)
BR (1) BR112023013790A2 (https=)
WO (1) WO2022148480A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4410371A1 (en) * 2023-02-03 2024-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Therapeutic vhh antibodies against alpha-hemolysin from staphylococcus aureus
CN118480121B (zh) * 2024-05-13 2025-04-01 重庆原伦生物科技有限公司 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130164308A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
JP2014508748A (ja) * 2011-02-08 2014-04-10 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
JP2020504759A (ja) * 2017-01-03 2020-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AR097648A1 (es) 2013-09-13 2016-04-06 Amgen Inc Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
WO2020041394A1 (en) * 2018-08-23 2020-02-27 Trustees Of Tufts College Binding proteins, compositions and methods thereof for neutralization of infection of pathogens having a type iii secretion system
CN109705213B (zh) * 2018-12-04 2023-04-18 上海长征医院 抗金黄色葡萄球菌毒素抗体及其用途
CN110577594B (zh) * 2019-08-19 2021-05-14 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a21、应用及试剂盒
CN110526967A (zh) * 2019-08-19 2019-12-03 西北农林科技大学 一种金黄色葡萄球菌肠毒素a纳米抗体a13、应用及试剂盒
CN110526966B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b6、应用及试剂盒
CN110563839A (zh) * 2019-08-19 2019-12-13 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b1、应用及试剂盒
CN110526968B (zh) * 2019-08-19 2021-08-17 西北农林科技大学 一种金黄色葡萄球菌肠毒素b纳米抗体b7、应用及试剂盒

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014508748A (ja) * 2011-02-08 2014-04-10 メディミューン，エルエルシー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）α毒素に特異的に結合する抗体及び使用方法
US20130164308A1 (en) * 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
JP2020504759A (ja) * 2017-01-03 2020-02-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓ．ａｕｒｅｕｓ溶血素ａ毒素に対するヒト抗体

Also Published As

Publication number Publication date
US20240059764A1 (en) 2024-02-22
KR20230147616A (ko) 2023-10-23
CN117062908A (zh) 2023-11-14
EP4286409A4 (en) 2025-01-01
EP4286409A1 (en) 2023-12-06
WO2022148480A1 (zh) 2022-07-14
BR112023013790A2 (pt) 2023-10-03

Similar Documents

Publication Publication Date Title
TWI900705B (zh) Ｃｄ７３的抗原結合蛋白及其應用
US20240067747A1 (en) Cd73-binding protein and use thereof
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
CN112955548A (zh) 叶酸受体α特异性抗体
JP2024503425A (ja) 黄色ブドウ球菌のα毒素を標的とした抗原結合たんぱく質およびその応用
TWI846095B (zh) 抗cd47-cldn18.2雙特異性抗體及其用途
CN113264999B (zh) 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
CN114957460A (zh) 交叉中和金黄色葡萄球菌毒素的抗原结合蛋白及其用途
CN117843783A (zh) 抗人cd70抗体及其应用
US20240174736A1 (en) Antigen-binding protein targeting pneumolysin and use thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
CN116284406B (zh) 一种pd-1结合蛋白及其应用
CN119350502A (zh) 靶向fap的抗原结合蛋白及其应用
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
OA21922A (en) Antigen-binding protein targeting streptococcus pneumoniae hemolysin protein and use thereof.
OA21956A (en) Antigen-binding protein targeting staphylococcus aureus α-toxin and application thereof.
WO2025140296A1 (zh) 抗dll3抗体或其抗原结合片段及其用途
CN118715243A (zh) Cd39抗原结合蛋白及其应用
HK40089099A (en) Anti-tigit antibody and double antibody and their application
HK40092489A (zh) 抗cd47-cldn18.2双特异性抗体及其用途
HK40092489B (zh) 抗cd47-cldn18.2双特异性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230912

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230831

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20230831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260421